These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 30485777)

  • 1. The FDA Sentinel Initiative - An Evolving National Resource.
    Platt R; Brown JS; Robb M; McClellan M; Ball R; Nguyen MD; Sherman RE
    N Engl J Med; 2018 Nov; 379(22):2091-2093. PubMed ID: 30485777
    [No Abstract]   [Full Text] [Related]  

  • 2. FDA turns to electronic "sentinel" to flag prescription drug safety problems.
    Kuehn BM
    JAMA; 2008 Jul; 300(2):156-7. PubMed ID: 18612108
    [No Abstract]   [Full Text] [Related]  

  • 3. The FDA's sentinel initiative--A comprehensive approach to medical product surveillance.
    Ball R; Robb M; Anderson SA; Dal Pan G
    Clin Pharmacol Ther; 2016 Mar; 99(3):265-8. PubMed ID: 26667601
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessment of the impact of scheduled postmarketing safety summary analyses on regulatory actions.
    Sekine S; Pinnow EE; Wu E; Kurtzig R; Hall M; Dal Pan GJ
    Clin Pharmacol Ther; 2016 Jul; 100(1):102-8. PubMed ID: 26853718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exploring the FDA adverse event reporting system to generate hypotheses for monitoring of disease characteristics.
    Fang H; Su Z; Wang Y; Miller A; Liu Z; Howard PC; Tong W; Lin SM
    Clin Pharmacol Ther; 2014 May; 95(5):496-8. PubMed ID: 24448476
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Food and Drug Administration Adverse Event Reports of Retinal Vascular Occlusions Associated With Phosphodiesterase Type 5 Inhibitor Use.
    Li AS; Pomeranz HD
    J Neuroophthalmol; 2016 Dec; 36(4):480-481. PubMed ID: 27851718
    [No Abstract]   [Full Text] [Related]  

  • 7. Sequential surveillance for drug safety in a regulatory environment.
    Martin D; Gagne JJ; Gruber S; Izem R; Nelson JC; Nguyen MD; Ouellet-Hellstrom R; Schneeweiss S; Toh S; Walker AM
    Pharmacoepidemiol Drug Saf; 2018 Jul; 27(7):707-712. PubMed ID: 29504168
    [No Abstract]   [Full Text] [Related]  

  • 8. Role of postmarketing surveillance in contemporary medicine.
    Woodcock J; Behrman RE; Dal Pan GJ
    Annu Rev Med; 2011; 62():1-10. PubMed ID: 20809798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Drug makers' adverse event reports are often incomplete, US report finds.
    McCarthy M
    BMJ; 2015 Feb; 350():h651. PubMed ID: 25652561
    [No Abstract]   [Full Text] [Related]  

  • 10. The US Food and Drug Administration's Sentinel Initiative: expanding the horizons of medical product safety.
    Robb MA; Racoosin JA; Sherman RE; Gross TP; Ball R; Reichman ME; Midthun K; Woodcock J
    Pharmacoepidemiol Drug Saf; 2012 Jan; 21 Suppl 1():9-11. PubMed ID: 22262587
    [No Abstract]   [Full Text] [Related]  

  • 11. Miscategorization of Deaths in the US Food and Drug Administration Adverse Events Database.
    Meier L; Wang EY; Tomes M; Redberg RF
    JAMA Intern Med; 2020 Jan; 180(1):147-148. PubMed ID: 31589249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adverse drug events and near misses: who's counting?
    Wu AW
    Am J Med; 2000 Aug; 109(2):166-8. PubMed ID: 10967161
    [No Abstract]   [Full Text] [Related]  

  • 13. Increased reporting of cerebrovascular accidents with use of risankizumab observed in the Food and Drug Administration Adverse Events Reporting System (FAERS).
    Egeberg A; Thyssen JP
    Br J Dermatol; 2023 May; 188(6):793-794. PubMed ID: 36797979
    [No Abstract]   [Full Text] [Related]  

  • 14. MEDWatch: the new FDA medical products reporting program.
    Kessler DA
    Am J Hosp Pharm; 1993 Jun; 50(6):1151-2. PubMed ID: 8517452
    [No Abstract]   [Full Text] [Related]  

  • 15. MedWatch: the FDA medical products reporting program.
    Rheinstein PH
    Am Fam Physician; 1993 Sep; 48(4):636-8. PubMed ID: 8379493
    [No Abstract]   [Full Text] [Related]  

  • 16. Preface to supplement. Active surveillance of vaccine safety in the US Food and Drug Administration's Mini-Sentinel program: identification of exposures and outcomes.
    Vaccine; 2013 Dec; 31 Suppl 10():K1. PubMed ID: 24331068
    [No Abstract]   [Full Text] [Related]  

  • 17. Pediatric post-marketing safety systems in North America: assessment of the current status.
    McMahon AW; Wharton GT; Bonnel R; DeCelle M; Swank K; Testoni D; Cope JU; Smith PB; Wu E; Murphy MD
    Pharmacoepidemiol Drug Saf; 2015 Aug; 24(8):785-92. PubMed ID: 26098297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmarketing surveillance and reporting of adverse drug events.
    Baer RK
    S D J Med; 2004 Jan; 57(1):13-4. PubMed ID: 14964975
    [No Abstract]   [Full Text] [Related]  

  • 19. Uptake of new drugs in the early post-approval period in the Mini-Sentinel distributed database.
    Mott K; Graham DJ; Toh S; Gagne JJ; Levenson M; Ma Y; Reichman ME
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1023-32. PubMed ID: 27146123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Developing the Sentinel System--a national resource for evidence development.
    Behrman RE; Benner JS; Brown JS; McClellan M; Woodcock J; Platt R
    N Engl J Med; 2011 Feb; 364(6):498-9. PubMed ID: 21226658
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 13.